Tags

Type your tag names separated by a space and hit enter

Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial.
Osteoarthritis Cartilage 2006; 14(3):286-94OC

Abstract

OBJECTIVE

Osteoarthritis (OA) is the most common form of arthritis and the second most common cause of long-term disability among middle-aged and older adults in the United States. Methylsulfonylmethane (MSM) is a popular dietary supplement used as a single agent and in combination with other nutrients, and purported to be beneficial for arthritis. However, there is paucity of evidence to support the use of MSM.

METHODS

A randomized, double-blind, placebo-controlled trial was conducted. Fifty men and women, 40-76 years of age with knee OA pain were enrolled in an outpatient medical center. Intervention was MSM 3g or placebo twice a day for 12 weeks (6g/day total). Outcomes included the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician global assessments (disease status, response to therapy), and SF-36 (overall health-related quality of life).

RESULTS

Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P<0.05). No notable changes were found in WOMAC stiffness and aggregated total symptoms scores. MSM also produced improvement in performing activities of daily living when compared to placebo on the SF-36 evaluation (P<0.05).

CONCLUSION

MSM (3g twice a day) improved symptoms of pain and physical function during the short intervention without major adverse events. The benefits and safety of MSM in managing OA and long-term use cannot be confirmed from this pilot trial, but its potential clinical application is examined. Underlying mechanisms of action and need for further investigation of MSM are discussed.

Authors+Show Affiliations

Southwest College Research Institute, Southwest College of Naturopathic Medicine and Health Sciences, Tempe, AZ 85282, USA. l.kim@scnm.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16309928

Citation

Kim, L S., et al. "Efficacy of Methylsulfonylmethane (MSM) in Osteoarthritis Pain of the Knee: a Pilot Clinical Trial." Osteoarthritis and Cartilage, vol. 14, no. 3, 2006, pp. 286-94.
Kim LS, Axelrod LJ, Howard P, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthr Cartil. 2006;14(3):286-94.
Kim, L. S., Axelrod, L. J., Howard, P., Buratovich, N., & Waters, R. F. (2006). Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis and Cartilage, 14(3), pp. 286-94.
Kim LS, et al. Efficacy of Methylsulfonylmethane (MSM) in Osteoarthritis Pain of the Knee: a Pilot Clinical Trial. Osteoarthr Cartil. 2006;14(3):286-94. PubMed PMID: 16309928.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. AU - Kim,L S, AU - Axelrod,L J, AU - Howard,P, AU - Buratovich,N, AU - Waters,R F, Y1 - 2005/11/23/ PY - 2005/05/02/received PY - 2005/10/08/accepted PY - 2005/11/29/pubmed PY - 2006/5/4/medline PY - 2005/11/29/entrez SP - 286 EP - 94 JF - Osteoarthritis and cartilage JO - Osteoarthr. Cartil. VL - 14 IS - 3 N2 - OBJECTIVE: Osteoarthritis (OA) is the most common form of arthritis and the second most common cause of long-term disability among middle-aged and older adults in the United States. Methylsulfonylmethane (MSM) is a popular dietary supplement used as a single agent and in combination with other nutrients, and purported to be beneficial for arthritis. However, there is paucity of evidence to support the use of MSM. METHODS: A randomized, double-blind, placebo-controlled trial was conducted. Fifty men and women, 40-76 years of age with knee OA pain were enrolled in an outpatient medical center. Intervention was MSM 3g or placebo twice a day for 12 weeks (6g/day total). Outcomes included the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician global assessments (disease status, response to therapy), and SF-36 (overall health-related quality of life). RESULTS: Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P<0.05). No notable changes were found in WOMAC stiffness and aggregated total symptoms scores. MSM also produced improvement in performing activities of daily living when compared to placebo on the SF-36 evaluation (P<0.05). CONCLUSION: MSM (3g twice a day) improved symptoms of pain and physical function during the short intervention without major adverse events. The benefits and safety of MSM in managing OA and long-term use cannot be confirmed from this pilot trial, but its potential clinical application is examined. Underlying mechanisms of action and need for further investigation of MSM are discussed. SN - 1063-4584 UR - https://www.unboundmedicine.com/medline/citation/16309928/Efficacy_of_methylsulfonylmethane__MSM__in_osteoarthritis_pain_of_the_knee:_a_pilot_clinical_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1063-4584(05)00285-2 DB - PRIME DP - Unbound Medicine ER -